EUVIMEDEUVIMED entdecken
Crossref

Screen Failures and Causes in Inflammatory Bowel Disease Randomized Controlled Trials: A Study of 16 913 Screened Patients

Mathieu Uzzan iD, Georgi Georgiev, Laurent Peyrin-Biroulet, Yoram Bouhnik, Neeraj Narula, Vipul Jairath, Ryan Ungaro iD, Johan Burisch iD, Julien Kirchgesner, Bram Verstockt, Fez Hussain, Walter Reinisch iD

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Mathieu Uzzan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Paris Est Créteil University UPEC, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Gastroenterology Department, Fédération Hosp…. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Crohn Disease, Patient Selection, Colitis, Ulcerative. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

While recruitment rates in inflammatory bowel disease (IBD) trials are continuously decreasing, the underlying reasons are likely multifactorial but remain poorly defined. Screen failure (SF) proportions and causes have not been extensively explored in IBD.

Aim

We assessed SF proportions and underlying SF reasons in IBD phase 2 and 3 clinical trials.

Methods

We analyzed SF-related data from 17 randomized controlled phase 2 or 3 IBD trials. Twelve trials were in ulcerative colitis (UC) and 5 trials were in Crohn’s disease (CD) operated by a single contract research organization, IQVIA. Differences between patient groups were tested for significance by Mann-Whitney and Fisher’s tests when appropriate.

Results

We analyzed a total of 11 161 patients with UC and 5752 patients with CD. The mean SF proportion was 0.43 per trial in UC. The primary reason for SFs in UC was not meeting the overall (modified) Mayo score inclusion threshold and/or the endoscopic subscore of at least 2 (33.8% of all SF). In CD clinical trials, the mean SF proportion was at 0.53. The primary cause for SFs was not meeting the CDAI eligibility criteria (23.1% of all SFs). SF proportions were significantly higher in CD versus UC trials (P = .027). Clostridium difficile or any other intestinal infection and not meeting tuberculosis screening criteria were other major reasons for SFs both in UC and CD.

Conclusion

High SF proportion in IBD clinical trials, particularly for CD studies, pose obstacles to patient recruitment. While underlying causes are diverse, arbitrarily defined clinical and/or endoscopic eligibility criteria remain the major limiting factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Randomized Controlled Trials as TopicCrohn DiseasePatient SelectionColitis, UlcerativeMass ScreeningInflammatory Bowel DiseasesHumansMaleFemaleAdultPrognosisMiddle Aged

Stichwörter der Autor:innen

IBDclinical trialsdrug developmentscreen failure

Autor:innen und Institutionen

  • Paris Est Créteil University UPEC, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Gastroenterology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Crét…
  • IQVIA, IBD Department, Sofia, Bulgaria.
  • Department of Gastroenterology, Nancy University Hospital Inserm NGERE U1256, Lorraine University, Vandoeuvre-Les-Nancy, France.
  • Paris IBD Center, Groupe Hospitalier Privé Ambroise Paré-Hartmann, Neuilly-sur-Seine, France.
  • Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, Hamilton, ON, Canada.
  • McMaster University, Hamilton, ON, Canada.

ORCID-Profile: Mathieu Uzzan, Ryan Ungaro, Johan Burisch, Walter Reinisch

Zitieren

APA

Uzzan, M., Georgiev, G., Peyrin-Biroulet, L., Bouhnik, Y., Narula, N., Jairath, V., Ungaro, R., Burisch, J., Kirchgesner, J., Verstockt, B., Hussain, F., & Reinisch, W. (2025). Screen Failures and Causes in Inflammatory Bowel Disease Randomized Controlled Trials: A Study of 16 913 Screened Patients. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae233

Vancouver

Uzzan M, Georgiev G, Peyrin-Biroulet L, Bouhnik Y, Narula N, Jairath V, et al. Screen Failures and Causes in Inflammatory Bowel Disease Randomized Controlled Trials: A Study of 16 913 Screened Patients. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae233

BibTeX
@article{Uzzan2025,
  author = {Uzzan, Mathieu and Georgiev, Georgi and Peyrin-Biroulet, Laurent and Bouhnik, Yoram and Narula, Neeraj and Jairath, Vipul and Ungaro, Ryan and Burisch, Johan and Kirchgesner, Julien and Verstockt, Bram and Hussain, Fez and Reinisch, Walter},
  title = {Screen Failures and Causes in Inflammatory Bowel Disease Randomized Controlled Trials: A Study of 16 913 Screened Patients},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae233}
}
Kostenlos starten →